
EYLEA HD® 8 mg Data at Angiogenesis 2026 Highlight Robust Retinal Disease Profile
EYLEA HD® (aflibercept) 8 mg Data Presented at Angiogenesis 2026 Highlight Robust Clinical Profile in Treating Serious Retinal Diseases Regeneron Pharmaceuticals, Inc. today announced upcoming presentations from its ophthalmology portfolio…












